Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase I/II Clinical Trial of CPI-613^® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.